摘要
目的观察并探讨西格列汀联合阿卡波糖治疗2型糖尿病(T2DM)患者的临床疗效。方法选取2022年1月—2023年1月该院收治的110例T2DM患者为研究对象,采用随机数字表法分为两组,各55例。两组患者均接受常规指导,如饮食及运动等,对照组采用阿卡波糖治疗,观察组采用西格列汀联合阿卡波糖治疗。对比两组临床疗效、治疗前后血清炎性因子、血糖指标及不良反应。结果治疗后,观察组白细胞介素-6(5.03±0.83)ng/L、C反应蛋白(3.45±0.76)ng/L、肿瘤坏死因子-α(8.06±3.52)mg/L均低于对照组,组间差异有统计学意义(P<0.05);观察组空腹血糖(7.51±1.02)mmol/L、餐后2 h血糖(8.86±1.56)mmol/L、糖化血红蛋白(7.22±1.16)%、空腹胰岛素(80.42±11.41)mmol/L均低于对照组,组间差异有统计学意义(P<0.05)。观察组治疗总有效率为87.27%,高于对照组的67.27%,差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论西格列汀联合阿卡波糖治疗T2DM患者疗效确切,可有效改善血糖水平并降低机体炎症反应,且治疗安全性较好,值得临床推广。
Objective To observe and explore the clinical efficacy of sitagliptin combined with acarbose in the treatment of type 2 diabetes mellitus(T2DM).Methods 110 T2DM patients admitted to our hospital from January 2022 to January 2023 were selected as the study objects and divided into two groups by random number table method,with 55 cases in each group.Both groups received routine instructions,such as diet and exercise,the control group was treated with acarbose,the observation group was treated with sitagliptin combined with acarbose.The clinical efficacy,serum inflammatory factors and blood glucose indexes before and after treatment and adverse reactions were compared between the two groups.Results After treatment,interleukin-6(5.03±0.83)ng/L,C-reactive protein(3.45±0.76)ng/L,and tumor necrosis factor-α(8.06±3.52)mg/L in the observation group were all lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).fasting plasma glucose(7.51±1.02)mmol/L,2-hour postprandial blood glucose(8.86±1.56)mmol/L,glycated hemoglobin(7.22±1.16)%and fasting insulin(80.42±11.41)mmol/L in observation group were lower than those in control group,and the differences between the groups were statistically significant(P<0.05).The total effective rate of the observation group was 87.27%,higher than 67.27%of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sitagliptin combined with acarbose is effective in the treatment of T2DM patients,which can effectively improve blood sugar level and reduce inflammation in the body,and the treatment safety is good,worthy of clinical promotion.
作者
康莉
张艳艳
KANG Li;ZHANG Yanyan(Department of General internal medicine,Gansu Heping Hospital,Lanzhou Gansu,730030,China)
出处
《反射疗法与康复医学》
2023年第11期159-161,173,共4页
Reflexology And Rehabilitation Medicine
关键词
2型糖尿病
西格列汀
阿卡波糖
血清炎性因子
血糖
不良反应
Type 2 diabetes
Sitagliptin
Acarbose
Serum inflammatory factors
Blood sugar
Adverse reactions
作者简介
康莉(1977-),女,甘肃兰州人,本科,主治医师,研究方向:糖尿病的治疗与管理。
